Abstract: A system for determining context and intent in a conversation using machine learning (ML) based artificial intelligence (AI) in omni channel data communications is disclosed. The system may comprise a data store to store and manage data within a network, a server to facilitate operations using information from the one or more data stores, and a ML-based AI subsystem to communicate with the server and the data store in the network. The ML-based AI subsystem may comprise a data access interface to receive data associated with a conversation with a user via a communication channel. The ML-based AI subsystem may comprise a processor to provide a proactive, adaptive, and intelligent conversation by applying hierarchical multi-intent data labeling framework, training at least one model with training data, and generating and deploying a production-ready model based on the trained and retained at least one model.

Abstract: A system for a digital content security and communications system using an artificial intelligence (AI) based machine learning and predictive analysis is disclosed. The system may comprise a data store to store and manage data within a network, a server to facilitate operations using information from the one or more data stores, and an analytics subsystem to communicate with the server and the data store in the network. The analytics subsystem may comprise a data access interface to receive communication data from a user via a first communication channel. The analytics subsystem may comprise a processor to provide a proactive, adaptive, and intelligent conversation with the user via a second communication channel.

Abstract: The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: A system for determining context and intent in a conversation using machine learning (ML) based artificial intelligence (AI) in omni channel data communications is disclosed. The system may comprise a data store to store and manage data within a network, a server to facilitate operations using information from the one or more data stores, and a ML-based AI subsystem to communicate with the server and the data store in the network. The ML-based AI subsystem may comprise a data access interface to receive data associated with a conversation with a user via a communication channel. The ML-based AI subsystem may comprise a processor to provide a proactive, adaptive, and intelligent conversation by applying hierarchical multi-intent data labeling framework, training at least one model with training data, and generating and deploying a production-ready model based on the trained and retained at least one model.

Abstract: A system for determining context and intent in a conversation using machine learning (ML) based artificial intelligence (AI) in omnichannel data communications is disclosed. The system may comprise a data store to store and manage data within a network, a server to facilitate operations using information from the one or more data stores, and a ML-based AI subsystem to communicate with the server and the data store in the network. The ML-based AI subsystem may comprise a data access interface to receive data associated with a conversation with a user via a communication channel. The ML-based AI subsystem may comprise a processor to provide a proactive, adaptive, and intelligent conversation by applying hierarchical multi-intent data labeling framework, training at least one model with training data, and generating and deploying a production-ready model based on the trained and retained at least one model.

Abstract: A system for artificial intelligence (AI) based omnichannel data communications is disclosed. The system may comprise a data store to store and manage data within a network, a server to facilitate operations using information from the one or more data stores, and an analytics subsystem to communicate with the server and the data store in the network. The analytics subsystem may comprise a data access interface to receive communication data from a user via a first communication channel. The analytics subsystem may comprise a processor to provide a proactive, adaptive, and intelligent conversation with the user via a second communication channel. The system may also comprise an output interface to transmit the at least one appropriate response to the user at a user device using any number of AI-based and data processing techniques to better identify customer touchpoints and improve customer journey and experience during customer engagement scenarios.

Abstract: A system for artificial intelligence (AI) based omnichannel data communications is disclosed. The system may comprise a data store to store and manage data within a network, a server to facilitate operations using information from the one or more data stores, and an analytics subsystem to communicate with the server and the data store in the network. The analytics subsystem may comprise a data access interface to receive communication data from a user via a first communication channel. The analytics subsystem may comprise a processor to provide a proactive, adaptive, and intelligent to conversation with the user via a second communication channel. The system may also comprise an output interface to transmit the at least one appropriate response to the user at a user device using any number of AI-based and data processing techniques to better identify customer touchpoints and improve customer journey and experience during customer engagement scenarios.

Abstract: A reloadable magazine apparatus that accepts two or more cartridges that enables users to quickly load a plurality of cartridges into the magazine through a loading window, for use in a firearm. Embodiments of the invention enable a user to place a clip of cartridges directly in the magazine, for example a stripper clip, and rapidly load the magazine. Embodiments of the invention enable the magazine to be configured for use in capacity and removable magazine restricted states through the incorporation of ammunition stops and locking tabs.

Abstract: The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: The present disclosure describes PD-L1 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: The present disclosure describes gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: The present disclosure describes IFN-? gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: The present invention provides, inter alia, methods for treating tumors that are sensitive to an IGF1R inhibitor. The tumor are determined to be sensitive if the level of IGF1 mRNA expression in the tumor cells, relative to one or more reference genes, reaches a certain threshold level. Methods for evaluating patients as candidates for receipt of the IGF1R inhibitor therapy are also provided as well along with in vitro assay methods and kits for performing any of the methods.

Abstract: The present invention may be used in systems for non-volatile memory storage of electronic data. A first substrate member may have a first and second surface with a first and second substrate connector spaced apart and attached to the first surface and a first and second spacer element spaced apart and attached to said second surface. A NAND flash controller device may be mounted on the first surface and connected to the substrate connectors and spacer elements. Multiple NAND memory devices may be mounted on the second surface and be connected to the NAND flash controller device. A second substrate member may have a first and second surface with multiple NAND flash memory devices mounted on at least one of the surfaces. The second substrate member may be attached to the spacer elements on the first surface and said multiple NAND flash memory devices may be connected to the NAND flash controller device.

Abstract: Disclosed are systems and methods for live broadcasting of one or more media streams, such as audio streams, via the internet such that it is accessible substantially by a number of listeners at a number of locations. Said system is operable such that the contents of each of said one or more media streams can originate from a call or other communication from a conventional telephony device which does not require internet connection.

Abstract: A continuous throttle regulation device employs a motor throttle body located proximate to a motor or engine, and an accelerator pedal located remote from the motor or engine. A return switch (RS) is responsive to the motor throttle body, and a pressure sensitive switch (PSS) is responsive to the accelerator pedal position. Power is passed through both switches then to a critical electronic element required to run the motor, such as a distributor. Therefore, when both switches are open, power to the critical element is interrupted, slowing or stopping the motor. When both switches are closed, the power is restored to the ignition causing the motor to operate. Therefore, the system may engage and disengage automatically and intermittently numerous times in a short period of time, thereby safely limiting motor speed, while restoring power in a split second to keep the motor running and operational. This technology may also be applied to gasoline, diesel, and electric motors to regulate their operation.

Abstract: A continuous throttle regulation device employs a motor throttle body located proximate to a motor or engine, and an accelerator pedal located remote from the motor or engine. A return switch (RS) is responsive to the motor throttle body, and a pressure sensitive switch (PSS) is responsive to the accelerator pedal position. Power is passed through both switches then to a critical electronic element required to run the motor, such as a distributor. Therefore, when both switches are open, power to the critical element is interrupted, slowing or stopping the motor. When both switches are closed, the power is restored to the ignition causing the motor to operate. Therefore, the system may engage and disengage automatically and intermittently numerous times in a short period of time, thereby safely limiting motor speed, while restoring power in a split second to keep the motor running and operational. This technology may also be applied to gasoline, diesel, and electric motors to regulate their operation.

Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

Abstract: The present invention provides the identification of genes that are expressed in tumors that are responsive to a given therapeutic agent and whose expression (either increased expression or decreased expression) correlates with responsiveness to that therapeutic agent. One or more of the genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by that agent.

Abstract: The present invention provides a method of inhibiting influenza and flaviviral replication based on a mechanism of action in which HA-mediated fusion or E protein mediated fusion is inhibited by a fusion inhibiting agent which binds, complexes or otherwise becomes associated with HA or E protein during the translation of the target protein and/or its vesicular transport.